Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021

SELL
$18.21 - $23.2 $24,128 - $30,740
-1,325 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$15.39 - $22.1 $20,391 - $29,282
1,325 New
1,325 $26,000
Q2 2020

Aug 12, 2020

SELL
$13.31 - $19.41 $13 - $19
-1 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$13.06 - $21.24 $13 - $21
1 New
1 $0
Q4 2019

Feb 14, 2020

SELL
$17.29 - $21.74 $98,259 - $123,548
-5,683 Closed
0 $0
Q3 2019

Nov 12, 2019

BUY
$19.51 - $24.28 $94,779 - $117,952
4,858 Added 588.85%
5,683 $111,000
Q2 2019

Aug 12, 2019

BUY
$21.47 - $37.33 $17,712 - $30,797
825 New
825 $19,000
Q1 2019

May 10, 2019

SELL
$28.4 - $36.49 $31,524 - $40,503
-1,110 Closed
0 $0
Q4 2018

Feb 13, 2019

SELL
$27.94 - $44.61 $58,981 - $94,171
-2,111 Reduced 65.54%
1,110 $33,000
Q3 2018

Nov 09, 2018

SELL
$38.6 - $46.12 $481,650 - $575,485
-12,478 Reduced 79.48%
3,221 $137,000
Q2 2018

Aug 08, 2018

BUY
$40.56 - $51.36 $636,751 - $806,300
15,699 New
15,699 $646,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.53B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Twin Tree Management, LP Portfolio

Follow Twin Tree Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twin Tree Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Twin Tree Management, LP with notifications on news.